drugset / Trial / NCT02737332

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02737332

Phase 2 Completed 53 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as Compared to Abiraterone Acetate

Timeline

Start
2016-03-21
Primary completion
2017-02-27
Completion
2017-02-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abiraterone acetate Small molecule 500 mg
Comparator Abiraterone acetate Small molecule 1000 mg

Indications